Mather Group
UTHR icon

Mather Group’s United Therapeutics UTHR Stock Holding History

Mather Group’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$9.8K Buy
+18
New +$9.31K ﹤0.01% 1653
2024
Q2 		– Sell
-8
Closed -$1.76K – 2278
2024
Q1 		$1.76K Buy
+8
New +$1.8K ﹤0.01% 1565

Other funds holding UTHR

AssetMark Inc
AssetMark Inc Concord, California $59.5B AUM 15.92% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Atwood & Palmer
Atwood & Palmer Kansas City, Missouri $1.95B AUM 16% 1-Year Est. Return
KBC Group
KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return
Polaris Capital Management
Polaris Capital Management Boston, Massachusetts $953M AUM 27.74% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return
Fjarde Ap-fonden
Fjarde Ap-fonden Stockholm, Sweden $19.4B AUM 31.69% 1-Year Est. Return
Livforsakringsbolaget Skandia
Livforsakringsbolaget Skandia Stockholm, Sweden $3.02B AUM 43.19% 1-Year Est. Return
Nepsis Inc
Nepsis Inc Minneapolis, Minnesota $317M AUM 37.22% 1-Year Est. Return

Mather Group's UTHR Position: Q3 2026 in Review

Mather Group opened a new position in United Therapeutics (UTHR) in Q3 2026: 18 shares worth $9.8K. The stake represents ﹤0.01% of the portfolio and ranks #1653 among its holdings. This is a return to the name: Mather Group previously reported a position in UTHR as recently as Q1 2024.

Mather Group first reported a position in UTHR in Q1 2024 and has held it in 2 quarters since. 165 funds tracked by Wall St. Rank hold UTHR as of Q3 2026.

  • Mather Group held 18 shares of United Therapeutics worth $9.8K as of Q3 2026.
  • United Therapeutics was a new Mather Group position in Q3 2026.
  • United Therapeutics made up ﹤0.01% of Mather Group's portfolio in Q3 2026, its #1653 holding.
  • Mather Group first reported a position in United Therapeutics in Q1 2024 and has held it in 2 quarters since.
  • 165 funds tracked by Wall St. Rank held United Therapeutics as of Q3 2026.

Based on Mather Group's 13F filing for Q3 2026, filed 14 Oct 2026.